

1
2
3 1 A population-based case control study evaluating the risk of acquiring malaria in those visiting
4 2 friends and relatives (VFR) in Calgary, Canada (2013 – 2017)
5
6

7 4 Dewdunee H. Marasinghe BSc¹, James Cheaveau BSc, MBBS², Bonnie Meatherall MD, MSc³,
8 5 Susan Kuhn MD, MSc⁴, Stephen Vaughan MD³, Rudolf Zimmer MD⁵, Dylan R. Pillai MD, PhD^{2,3,6}
9
10

- 11
12 8 1. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University,
13 9 Montreal, PQ, Canada
14 10 2. Department of Microbiology, Immunology, and Infectious Diseases, University of Calgary,
15 11 AB, Canada
16 12 3. Department of Medicine, University of Calgary, Calgary, AB, Canada
17 13 4. Department of Pediatrics, University of Calgary, Calgary, AB, Canada
18 14 5. Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada
19 15 6. Department Pathology and Laboratory Medicine, University of Calgary, Calgary, AB,
20 16 Canada
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 22 Corresponding author:

37 23 Dylan Pillai MD, PhD

38 24 Departments of Pathology, Medicine, and MIID

39 25 University of Calgary

40 26 9-3535 Research Road NW, 1W-416

41 27 Calgary, AB, Canada, T2L2K8

42 28 drpillai@ucalgary.ca

43 29 T: 403-770-3338

44 30 F: 403-770-3347
45
46
47
48
49

50 32
51 33 Funding Statement: This work was funded by Calgary Laboratory Services

52 34 Conflict of interest: The authors declare no conflicts of interest
53
54

55 36 Word count: 2470

56 37 Number of figures and tables: 3 figures and 2 tables
57
58
59
60

1
2
3 **38 Abstract**
4
5

6 **39 Background:** The immigrant population from malaria endemic areas in Canada is steadily
7
8
9 40 increasing and with this comes the increased risk of imported malaria. The primary objective of
10
11 41 this study was to analyze the incidences of malaria in the Calgary area among those visiting
12
13 42 friends and relatives (VFR) population in comparison to other travelers. Furthermore, we
14
15
16 43 attempted to investigate if pediatric VFR travelers were at a higher risk of being diagnosed with
17
18
19 44 malaria.
20

21 **45 Methods:** We conducted a case-control study of 1348 symptomatic returning travelers
22
23
24 46 presenting for malaria testing in Calgary from 2013 – 2017, to compare the epidemiological risk
25
26
27 47 factors between those who tested malaria positive and negative using routinely collected data
28
29 48 from Calgary Laboratory Services database. Multivariable logistic regression was used to analyze
30
31 49 the association between the presence of malaria and other risk factors.
32
33

34 **50 Results:** The odds of a VFR traveler being diagnosed with malaria was 2.82 [1.42-5.92] times
35
36
37 51 greater than that of a non-VFR traveler. Adults travelers were 3.62 [1.66-8.84] more likely to be
38
39
40 52 diagnosed with malaria compared to pediatric travelers controlling for other variables including
41
42 53 traveler status. VFR travelers were significantly less likely to seek pre-travel advice (27%), take
43
44 54 prophylaxis (18%) and more likely to stay longer than two weeks (93%) compared to other
45
46
47 55 travelers.
48

49
50 **56 Discussion:** These data suggest that targeted strategies to provide pre-travel care to VFR
51
52 57 travelers may aid in reducing the burden of malaria during and after travel. The potential savings
53
54
55 58 to the health care system with reducing VFR malaria needs to be assessed further.
56
57
58
59
60

59 Introduction

60 In 2017, there were 219 million malaria cases and 435 000 fatalities worldwide, with \$3.1 billion
61 USD allocated globally for malaria eradication and management (1). 92% of all malaria cases and
62 93% of malaria deaths occurred in the WHO African Region (1). Even though Canada is not
63 considered as an endemic malaria region, annually there are an approximately 488 imported
64 malaria cases a year according to the 2010 – 2014 trends (2). Furthermore, the Canadian
65 immigrant population from the malaria-endemic regions has been increasing over the past years.
66 Specifically, in the Calgary metropolitan area, 4.3% of the population recognized themselves as
67 belonging to an African ethnic origin and 27.9% of the population identified themselves as
68 belonging to an Asian ethnic origin (3). Additionally, 37.5% of all Canadian children currently are
69 either first- or second-generation immigrants (4).

70 Following the recommendations of Barnett et al. (2010), VFRs were defined for this study as the
71 population of returning travelers who had recently visited a malaria endemic region for the
72 purpose of visiting friends and relatives (5). Immigrants contribute to the VFR population, but not
73 all immigrants will necessarily return to their country of origin. Moreover, other Canadians may
74 be married to immigrants, and travel to visit in-laws with the same risk as the spouse. For the
75 purpose of this study, VFR travel was not classified according to ethnic origin or immigration
76 status but on the reason for travel. As such, this definition captured those who had connections
77 to the local population, but did not qualify as a VFR under traditional definitions (5). The VFR
78 population is known to be at a higher risk of being diagnosed with travel-related illnesses in
79 general (6-8). VFRs are likely to make travel plans at short notice, likely to including dependent
80 children, and stay in rustic family settings (9). The unique travel characteristics of this group put

1
2
3 81 them at increased risk of contracting malaria compared with groups traveling for other reasons.
4
5
6 82 VFR travelers are more likely to visit malaria-endemic areas, make regular visits to same regions,
7
8 83 and stay for long durations (6-10). Within malaria-endemic regions, VFR travelers are more likely
9
10
11 84 to visit areas within countries defined by WHO as high risk for malaria such as rural remote
12
13 85 locations (11). Local family accommodations are often more basic than that used by tourists,
14
15 86 including less likelihood of air conditioning and indoor residual spraying (10, 11). VFR travelers
16
17
18 87 are less likely to use personal protection such as long sleeve clothing, mosquito nets and insect
19
20
21 88 repellent (10). Finally, some VFR travelers may downgrade their risk perception due to a faulty
22
23 89 belief in ongoing protection from past exposure to malaria exposure prior to coming to Canada.
24
25 90 This may be a reason that some may avoid taking effective antimalarial prophylaxis (6-12).
26
27
28 91 Children of first and second-generation immigrants are also at a higher risk for travel-related
29
30 92 illnesses than non-VFR travelers (9, 13). Canadian-born VFR travelers are exposed to the same
31
32
33 93 hazards as their immigrant parents, but are naïve to many travel-related illnesses foreign to
34
35 94 Canada. This places them at higher risk compared with recent immigrants of developing severe
36
37
38 95 malaria with increased morbidity and mortality (9). Compared to adults, VFR children are also
39
40 96 more likely to have delays in treatment due to greater likelihood of initial misdiagnosis, as well
41
42
43 97 as higher parasitemia (14-17).
44
45
46 98 In Canada, the number of imported malaria cases has steadily risen since 2000 (12, 18). A
47
48 99 previous study of returning travelers in Calgary done by this group found that the majority
49
50
51 100 belonged to the VFR travel group (12). Therefore, the primary objective of the study was to
52
53 101 rigorously investigate the epidemiological characteristics of VFR and compare them to other
54
55 102 returning travelers using case-controlled multivariable logistic regression.
56
57
58
59
60

103 **Methods**

104 *Study design*

105 We conducted a case-control study of symptomatic returning travelers presenting for malaria
106 testing in Calgary (Alberta, Canada) from 2013 – 2017, to compare the epidemiological risk
107 factors between those who tested malaria positive and negative. Calgary is a city of 1.4 million
108 people with a growing immigrant population. Malaria testing is handled by the centralized
109 Calgary Laboratory Services (CLS). When a malaria test is ordered, a malaria history form (MHF)
110 was required according to CLS protocol, to allow for data collection on epidemiological risk
111 factors. The CLS database was reviewed, which contained a record of all malaria diagnostic tests
112 requested during the study period. Subjects from the CLS database was linked to the MHF using
113 the laboratory accession number. Data collection took place between May-August 2018.
114 Observers recording information on MHFs were inherently blinded to the outcome of the patient
115 as they were completed before the diagnostic test was conducted, but investigators conducting
116 the analysis were not blinded. Individuals who were not symptomatic and undergoing testing for
117 alternative reasons (e.g. visa requirement) were excluded from the study. Ethical approval was
118 obtained from the Conjoint Health Research Ethics Board at the University of Calgary (REB 15-
119 1160).

120 *Case definition*

121 A case was defined as someone who had a clinical diagnosis of malaria. Each malaria test was
122 performed as per standard operating procedure at the time with three Giemsa-stained thick and
123 thin peripheral blood smears at least 6-8 hours apart and rapid diagnostic tests (RDTs)

1
2
3 124 (BinaxNOW® Malaria, Alere, USA). Malaria species were identified by microscopy. In house
4
5
6 125 polymerase chain reaction (PCR) was performed in cases where further confirmation was
7
8 126 required. Individuals undergoing repeated malaria tests within a three-month period were
9
10
11 127 included only once. All cases from 2013 – 2017, except for those that were excluded due to
12
13 128 malaria screening tests were included in the study.

14
15
16 129 *Selection of controls*

17
18
19 130 From individuals who tested negative using the same methods as described for a case, roughly
20
21
22 131 five controls were selected for each case matched to the year when the case was diagnosed. The
23
24 132 main purpose of this was to reduce the time taken performing chart reviews on the MHFs.
25
26
27 133 Further information regarding the randomization process and selection of controls is available in
28
29 134 the online supplementary material.

30
31
32 135 *Epidemiological risk factors*

33
34
35 136 Epidemiological data were collected on enrolled individuals prospectively by the testing clinician
36
37 137 on the MHF so that the relationship between malaria positivity and epidemiological risk factors
38
39 138 could be examined. Data entry into the study database was performed retrospectively via review
40
41
42 139 of the MHFs. Information from the original MHFs was complemented with information from
43
44 140 repeated MHFs and CLS database to reduce recall bias. Further information of the
45
46
47 141 epidemiological risk factors can be found in the supplementary material and a copy of the
48
49 142 standardized MHF is shown in supplementary figure 1.

50
51
52 143

53
54
55 144

145 *Statistical Analysis*

146 An initial descriptive analysis was conducted of the epidemiological risk factors of the study
147 population based on the outcome status. A multivariable analysis was conducted using only those
148 who traveled for the purpose of VFR, tourism or business. Other categories such as new
149 immigrants and visitors to Canada were excluded because they were not considered as returning
150 travelers. Differences in predisposing conditions between VFR and other travelers were
151 examined using Chi-square tests. Multivariable logistic regression was used to compare the odds
152 ratio for being in the VFR group versus other returning travelers and other risk factors/ potential
153 confounders between cases and controls.

154

155 **Results**

156 *Descriptive epidemiological analysis*

157 As seen in figure 1, there were 219 confirmed malaria cases and 1129 controls enrolled in this
158 study. Basic demographic and clinical characteristics of the study population stratified by malaria
159 status are described in table 1. *P. falciparum* was the most commonly detected malaria parasite
160 (65.8%) in this study, followed by *P. vivax* (24.7%). Percentage of males in the malaria positive
161 group (64.8%) was significantly higher compared to the control group (51.3%; p-value <0.001).
162 The most common age of travel was 33 years-old for cases and 35 for controls and this was not
163 significantly different between the two groups (p-value 0.147). VFR was the most common type
164 of traveler among both cases (49.7%) and controls (46.6%). Among those who tested positive for
165 malaria, Africa was the most common travel destination (79.7%) whereas Asia was the most

1
2
3 166 commonly traveled destination among those who tested negative for malaria (48.7%). Those who
4
5
6 167 tested negative for malaria sought pre-travel advice significantly more often (35.9%) compared
7
8 168 to those who tested positive (19.6%; p-value <0.001). The percentage taking prophylaxis was not
9
10
11 169 significantly different between cases and controls (p-value 0.267). Percentage of participants that
12
13 170 reported headache as a symptom was significantly higher in cases (65%) compared to controls
14
15 171 (51%; p-value 0.001). Sore throat was observed significantly more among controls (25%) as
16
17
18 172 oppose to cases (12%; p-value <0.001). Other symptoms such as fever, cough and diarrhea were
19
20
21 173 marginally significant between cases and controls with only fever being observed at a higher
22
23 174 percentage among cases. Duration of travel (in days) for those who tested positive for malaria
24
25 175 was significantly higher (239) compared to those who tested negative (49; p-value <0.001. The
26
27
28 176 incidence of malaria was highest in municipal Ward 5, followed by Ward 9 and 10, which
29
30 177 corresponded to North East (NE) and South East (SE) quadrants in City of Calgary (Figure 2).

31
32
33 178

34 35 36 179 *Multivariable analysis*

37
38
39 180 VFR travelers were less likely to seek pre-travel advice (p-value < 0.001), take prophylaxis (p-value
40
41
42 181 = 0.002), and more likely to stay longer than 2 weeks (p-value < 0.001) compared with non-VFR
43
44 182 travelers (Figure 3). Controlling for other factors, being an adult (OR: 3.62 [1.66-8.84]), male (OR:
45
46
47 183 2.70 [1.56-4.80]), belonging to VFR population (OR: 2.82 [1.42-5.92]) and traveling to Africa (OR:
48
49 184 11.52 [6.33-22.05]) were factors that were significantly associated with testing positive for
50
51
52 185 malaria in this study population (Table 2). Seeking pre-travel advice was associated with testing
53
54 186 negative for malaria (OR: 0.38[0.20-0.70]; Table 2). There was no significant evidence to suggest

1
2
3 187 duration had an impact of being a case or a control (OR: 1.40 [0.60-3.67]; Table 2). Similarly, there
4
5
6 188 was no significant evidence of effect measure modification on the multiplicative scale between
7
8 189 VFR status and gender or region traveled to (Supplementary table 1 and 2).
9
10

11 190

14 191 **Discussion**

17 192 The primary aim of this study was to investigate risk factors associated with testing positive for
18
19
20 193 malaria among VFR travelers in the Calgary metropolitan area. 47% of the study population
21
22 194 belonged to the VFR population excluding those who did not have a traveler status reported in
23
24
25 195 MHFs. The highest proportion of those who were diagnosed with malaria also belonged to this
26
27 196 population. It was observed that VFRs were also less likely to seek pre-travel advice, take
28
29
30 197 prophylaxis, and stay less than 2 weeks compared to non-VFR travelers. These factors were
31
32 198 hypothesized to make the VFR population a high-risk group in acquiring malaria during their
33
34
35 199 travels (7, 12). Consequently, after controlling for other factors, VFRs were also more likely to be
36
37 200 diagnosed with malaria compared with other travelers. Travelling to Africa as well as being male
38
39
40 201 also increased the odds of being diagnosed with malaria independent of other factors.

42 202 Currently, Sub-Saharan Africa has the highest malaria burden among WHO regions with 95% of
43
44
45 203 malaria cases in 2016 originating from this region (1). Additionally, previous studies also found
46
47
48 204 that those who travel to the African continent carried the highest burden of imported malaria
49
50 205 (13, 19, 20). Thus, the observation in this study that those who traveled to the African continent
51
52 206 carry higher odds of being diagnosed with malaria corresponds to what has been previously
53
54
55 207 reported in other jurisdictions. Males were more likely to be diagnosed with malaria in this study
56
57
58
59
60

1
2
3 208 population. Likely explanations for this could be that they may disproportionately travel to the
4
5 209 highest risk malaria areas within risk destinations (e.g., rural, remote and repetitive travel) and/or
6
7
8 210 that they might take fewer personal protective measures (e.g., bed nets, repellent use) (21, 22)
9
10
11 211 Therefore, disparities between men and women regarding malaria diagnosis is an important
12
13 212 finding, where VFR men may be a hard-to-reach population that may need greater outreach
14
15 213 regarding pre-travel clinical prevention.

16
17
18 214 We were also interested in investigating VFR children being tested positive for malaria. It was
19
20
21 215 observed that children were less likely to be diagnosed with malaria compared with adults, when
22
23 216 controlled for the traveler status and other confounders. However, 7.8% of VFR children tested
24
25
26 217 in our study were diagnosed with malaria, as opposed to 0% of non-VFR pediatric travelers.
27
28 218 Regardless of the type of travel, parents are more likely to seek medical care for children
29
30
31 219 presenting with febrile symptoms than for themselves. Therefore, it is likely that this dataset
32
33 220 would represent a higher proportion of children with non-malaria causes for their febrile illnesses
34
35
36 221 compared with adults presenting with the same (23-25). This is likely to produce bias in the effect
37
38 222 measure, and to erroneously suggest that children are at a disproportionately lower risk of
39
40
41 223 malaria in comparison to adults. Due to the lack of a sufficient sample of non-VFR pediatric
42
43 224 travelers in our study, we could not establish evidence to support effect measure modification
44
45 225 between being a child and belonging to VFR population.

46
47
48 226 A major limitation of this study was that we only had information on those subjects, who
49
50
51 227 presented with malaria-like symptoms to a care facility. This likely introduced selection bias,
52
53 228 exaggerating the effect measure. Additionally, VFR travelers were not distinguished according to
54
55
56 229 first- or second-generation immigration status. It would have been valuable to make this
57
58
59
60

1
2
3 230 distinction, because risk perception about malaria and the use of personal protective measures
4
5
6 231 may differ between these subpopulations. Similarly, another subgroup that could be considered
7
8 232 is those who travel to malaria-endemic versus non-endemic areas. The potential for information
9
10 233 bias was overlooked in this study due to missing information. Despite these limitations, this study
11
12
13 234 is consistent with the findings previously published from other industrialized non-malarial
14
15 235 countries (6-8, 12, 18, 26). Therefore, this study adds to the growing body of knowledge regarding
16
17
18 236 the travel-related health burden among VFR travelers, and the need for better access to pre-
19
20 237 travel clinical prevention that suits the specific needs of various immigrant populations. This
21
22
23 238 study also directly investigated predisposing factors such as malaria prophylaxis use and
24
25 239 utilization of pre-travel health services within the international travel population presenting with
26
27
28 240 malaria-like symptoms in Calgary. Furthermore, the use of CLS database from the Calgary
29
30 241 metropolitan area may allow key findings to be generalizable to other major metropolitan areas
31
32
33 242 in Canada that have similar immigrant population demographics.

34
35
36 243 Even with published evidence to suggest that pre-travel clinical prevention in general helps to
37
38 244 reduce commonly-encountered health risks such as malaria, little has been done to create
39
40
41 245 programs or interventions tailored to the specific needs of high-risk VFR travelers regarding low-
42
43 246 cost immunization and chemoprophylaxis especially for dependent vulnerable children (10, 19,
44
45 247 26). Instead, VFR travelers are often treated health policy decision-makers as having the same
46
47
48 248 needs and ability to pay as well-headed tourists traveling to all-inclusive resorts for vacation. By
49
50 249 creating financial and structural barriers to pre-travel clinical prevention for high-risk groups such
51
52
53 250 as VFR travelers, an unnecessary burden is also placed on the publicly-funded health care system
54
55 251 in Canada dealing with expensive post-travel medical interventions for completely preventable
56
57
58
59
60

1
2
3 252 conditions. Previous studies suggest that financial support rather than education and awareness
4
5
6 253 is a more effective strategy in dealing with the health risks of the VFR population (27-30).
7
8 254 Currently in Canada, pre-travel clinical prevention has been defunded or delisted from publicly-
9
10 255 funded provincial health care services. VFR travelers and parents must pay completely out-of-
11
12 256 pocket for pre-travel health services as well as most if not all travel-related immunizations and
13
14 257 prophylaxis with or without public or private drug benefit plans. In addition, very few private
15
16 258 health organizations have access to publicly-funded language services to assist in reducing
17
18 259 iatrogenic mistakes with travelers where English is a second language. Finally, many VFR travelers
19
20 260 are working-class with limited funds for more than the cost of air fare. The cost of travel-related
21
22 261 vaccines and chemoprophylaxis can be more than one household can afford, especially if parents
23
24 262 are taking several children to visit grandparents, uncles and aunts. Until financial barriers to good
25
26 263 quality and appropriate VFR travel health services are reduced, we cannot assume that all cases
27
28 264 of malaria in this high-risk population is due solely to lack of awareness or lack of concern. We
29
30 265 advise that policy makers be more aware of the disparities of health outcomes in the traveler
31
32 266 population according to travel status (VFR vs non-VFR), and suggest providing financial support
33
34 267 to cover travel-related health expenses for those at greatest risk including children. Incidences
35
36 268 of malaria in the Calgary area during the study period was highest along the city's NE and SE
37
38 269 quadrant border, where most new Canadians now reside. Traveling populations in this area of
39
40 270 the city should be the focus of further study to determine community-based needs to reduce the
41
42 271 prevalence of malaria and other preventable conditions in these regions. Further investigation
43
44 272 regarding social factors such as risk perceptions, socioeconomic status and ability to pay, and
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 273 language barriers should be conducted to determine their impact on timely access to appropriate
4
5
6 274 pre-travel clinical prevention in Canada.
7

8
9 **275 Conclusion**

10
11
12 276 In this study, it was observed that VFR travelers were less likely to seek pre-travel advice, take
13
14 277 prophylaxis and were more likely to stay in a malaria-endemic area for a longer duration in
15
16
17 278 comparison to non-VFR recreational or business travelers. VFR travelers were also more likely to
18
19 279 be diagnosed with malaria than non-VFR travelers. We highlight the need for targeted and
20
21
22 280 subsidized pre-travel health services for the VFR population that goes beyond providing
23
24 281 awareness of risk factors when traveling internationally.
25
26

27 282

28
29
30 283

31
32
33 284

34
35
36 285

37
38
39 286

40
41
42 287

43
44
45 288

46
47
48 289

49
50
51 290

52
53
54 291

1
2
3 292
4
5
6
7 293
8
9

10 294 **References**

11
12 295 1. World Health Organization. World Malaria Report 2018. WHO Global Malaria Programme;
13
14 296 2018 2018 November 19.

15
16
17 297 2. Government of Canada. Surveillance of Malaria [Internet]. 2016 [updated 2016
18
19
20 298 November 17; cited 2018 June 11]. Available from: [https://www.canada.ca/en/public-](https://www.canada.ca/en/public-health/services/diseases/malaria/surveillance-malaria.html)
21
22 299 [health/services/diseases/malaria/surveillance-malaria.html](https://www.canada.ca/en/public-health/services/diseases/malaria/surveillance-malaria.html).

23
24
25 300 3. Statistics Canada. Canada [Country] and Calgary [Census metropolitan area], Alberta
26
27 301 (table). Census Profile. 2016 Census. Statistics Canada Catalogue no. 98-316-X2016001. [Online].
28
29 302 Ottawa2017 [updated 2019-01-14; cited 2019 February 08]. Available from:
30
31 303 <https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/index.cfm?Lang=E>.

32
33
34 304 4. Statistics Canada. Immigration and ethnocultural diversity: Key results from the 2016
35
36 305 Census [Internet]. 2017 [updated 2017 November 11; cited 2018 June 11]. Available from:
37
38 306 <https://www150.statcan.gc.ca/n1/daily-quotidien/171025/dq171025b-eng.htm>.

39
40
41 307 5. Barnett ED, MacPherson DW, Stauffer WM, Loutan L, Hatz CF, Matteelli A, et al. The
42
43 308 visiting friends or relatives traveler in the 21st century: time for a new definition. J Travel Med.
44
45 309 2010;17(3):163-70.

46
47
48 310 6. Ericsson CD, Hatz C, Leder K, Tong S, Weld L, Kain KC, et al. Illness in Travelers Visiting
49
50 311 Friends and Relatives: A Review of the GeoSentinel Surveillance Network. CID. 2006;43(9):1185-
51
52 312 93.
53
54
55
56
57
58
59
60

- 1
2
3 313 7. McCarthy AE, Morgan C, Prematunge C, Geduld J. Severe malaria in Canada, 2001-2013.
4
5
6 314 Malar J. 2015;14:151.
7
8 315 8. Fenner L, Weber R, Steffen R, Schlagenhauf P. Imported infectious disease and purpose
9
10 316 of travel, Switzerland. *Emerg Infect Dis.* 2007;13(2):217 - 22.
11
12
13 317 9. Bacaner N, Stauffer B, Boulware DR, Walker PF, Keystone JS. Travel Medicine
14
15 318 Considerations for North American Immigrants Visiting Friends and Relatives. *JAMA.*
16
17 319 2004;291(23):2856-64.
18
19
20 320 10. Pistone T, Guibert P, Gay F, Malvy D, Ezzedine K, Receveur MC, et al. Malaria risk
21
22 321 perception, knowledge and prophylaxis practices among travellers of African ethnicity living in
23
24 322 Paris and visiting their country of origin in sub-Saharan Africa. *Trans R Soc Trop Med Hyg.*
25
26 323 2007;101(10):990-5.
27
28
29 324 11. Dos Santos CC, Anvar A, Keystone JS, Kain KC. Survey of use of malaria prevention
30
31 325 measures by Canadians visiting India. *CMAJ.* 1999;160(2):195-200.
32
33
34 326 12. Lee CS, Gregson DB, Church D, Laupland KB, Eckhardt R, Ross T, et al. Population-based
35
36 327 laboratory surveillance of imported malaria in metropolitan Calgary, 2000-2011. *PLoS One.*
37
38 328 2013;8(4):e60751.
39
40
41 329 13. Hendel-Paterson B, Swanson SJ. Pediatric travelers visiting friends and relatives (VFR)
42
43 330 abroad: illnesses, barriers and pre-travel recommendations. *Travel Med Infect Dis.*
44
45 331 2011;9(4):192-203.
46
47
48 332 14. Lynk A, Gold R. Review of 40 children with imported malaria. *Pediatr Infect Dis J.*
49
50 333 1989;8(11):745-50.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 334 15. Viani RM, Bromberg K. Pediatric imported malaria in New York: delayed diagnosis. Clin
4
5
6 335 *Pediatr.* 1999;38(6):333-7.
7
8 336 16. Hexdall AH, Chiang WK. Malaria deaths following inappropriate malaria
9
10 337 chemoprophylaxis--United States, 2001. *Ann Emerg Med.* 2002;39(1):86.
11
12
13 338 17. Mascarello M, Allegranzi B, Angheben A, Anselmi M, Concia E, Lagana S, et al. Imported
14
15 339 malaria in adults and children: epidemiological and clinical characteristics of 380 consecutive
16
17 340 cases observed in Verona, Italy. *J Travel Med.* 2008;15(4):229-36.
18
19
20 341 18. Boggild AK, Geduld J, Libman M, Yansouni CP, McCarthy AE, Hajek J, et al. Malaria in
21
22 342 travellers returning or migrating to Canada: surveillance report from CanTravNet surveillance
23
24 343 data, 2004-2014. *CMAJ Open.* 2016;4(3):E352-E8.
25
26
27 344 19. Matteelli A, Carvalho AC, Bigoni S. Visiting relatives and friends (VFR), pregnant, and other
28
29 345 vulnerable travelers. *Infect Dis Clin North Am.* 2012;26(3):625-35.
30
31
32 346 20. Legros F, Bouchaud O, Ancelle T, Arnaud A, Cojean S, Le Bras J, et al. Risk factors for
33
34 347 imported fatal *Plasmodium falciparum* malaria, France, 1996-2003. *Emerg Infect Dis.*
35
36 348 2007;13(6):883.
37
38
39 349 21. Schlagenhauf P, Chen LH, Wilson ME, Freedman DO, Tcheng D, Schwartz E, et al. Sex and
40
41 350 gender differences in travel-associated disease. *CID.* 2010;50(6):826-32.
42
43
44 351 22. Phillips-Howard P, Radalowicz A, Mitchell J, Bradley D. Risk of malaria in British residents
45
46 352 returning from malarious areas. *BMJ.* 1990;300(6723):499-503.
47
48
49 353 23. Walsh A, Edwards H. Management of childhood fever by parents: literature review. *J Adv*
50
51 354 *Nurs.* 2006;54(2):217-27.
52
53
54
55
56
57
58
59
60

- 1
2
3 355 24. Karwowska A, Nijssen-Jordan C, Johnson D, Davies HD. Parental and health care provider
4
5
6 356 understanding of childhood fever: a Canadian perspective. *CJEM*. 2002;4(6):394-400.
7
8 357 25. Enarson MC, Ali S, Vandermeer B, Wright RB, Klassen TP, Spiers JA. Beliefs and
9
10 358 expectations of Canadian parents who bring febrile children for medical care. *Pediatrics*.
11
12 359 2012;peds. 2011-140.
13
14
15 360 26. Angell SY, Cetron MS. Health disparities among travelers visiting friends and relatives
16
17 361 abroad. *Ann Intern Med*. 2005;142(1):67 - 72.
18
19
20 362 27. Pistone T, Schwarzinger M, Chauvin P, Ezzedine K, Receveur M-C, Djossou F, et al.
21
22 363 Reimbursement of malaria chemoprophylaxis for travellers from Europe to Sub-Saharan Africa:
23
24 364 Cost-effectiveness analysis from the perspective of the French national health insurance system.
25
26 365 *Health Policy*. 2008;88(2-3):186-99.
27
28
29 366 28. Widmer LL, Blank PR, Van Herck K, Hatz C, Schlagenhauf P. Cost-effectiveness analysis of
30
31 367 malaria chemoprophylaxis for travellers to West-Africa. *BMC Infect Dis*. 2010;10(1):279.
32
33
34 368 29. Massad E, Behrens BC, Coutinho FA, Behrens RH. Cost risk benefit analysis to support
35
36 369 chemoprophylaxis policy for travellers to malaria endemic countries. *Malar J*. 2011;10(1):130.
37
38
39 370 30. Behrens RH, Neave PE, Jones CO. Imported malaria among people who travel to visit
40
41 371 friends and relatives: is current UK policy effective or does it need a strategic change? *Malar J*.
42
43 372 2015;14(1):149.
44
45
46
47
48 373
49
50
51 374
52
53
54 375
55
56
57
58
59
60

1
2
3 376
4
5

6 377
7
8

9 378 **Figure Legends**
10

11
12 379
13
14

15 380 Figure 1: Overview of study design. Only cases and controls who had the reason as “VFR”,
16
17 381 “Tourism” or “Business” were included in the multivariate analysis. Those who were excluded
18
19 382 due to “Missing Information” did not have their purpose of travel status specified in the malaria
20
21 383 history form (MHF). False positives were discrepant cases that were confirmed by PCR.
22
23
24
25

26 384
27
28

29 385 Figure 2: The incidences of Malaria in the Calgary area between 2013 - 2017 by municipal ward
30
31 386 boundaries. The locations for ward boundaries and population demographics were obtained
32
33 387 from The City of Calgary (Open Calgary, open data source).
34
35
36

37 388
38
39

40 389 Figure 3: The proportions of observing the specified predisposing conditions; (i) duration of stay
41
42 390 longer than two weeks (n = 241), (ii) seeking pre-travel advice (n = 779) and (iii) taking prophylaxis
43
44 391 (n = 736) within each traveler groups. P-values were calculated using Chi-square tests comparing
45
46 392 the two traveler groups
47
48
49

50
51 393
52
53

54 394
55
56
57
58
59
60

395

396

397 **Tables**

Table 1: Characteristics of the study population stratified by Malaria Status for symptomatic individuals (n = 1348)

Characteristic	Malaria Status		p value ^a
	No	Yes	
n	1129	219	
Gender Male (n) (%)	579 (51.3)	142 (64.8)	< 0.001
Age (mean (sd))	34.80 (21.05)	32.59 (18.01)	0.147
Reason (n ^b) (%)			< 0.001
Business	59 (6.3)	10 (5.6)	
New Immigrant	96 (10.3)	49 (27.7)	
Tourism	325 (34.9)	16 (9.0)	
VFR	433 (46.6)	88 (49.7)	
Visitor	17 (1.8)	14 (7.9)	
Continent (n ^b) (%)			< 0.001
Africa	313 (32.5)	145 (79.7)	
Americas	175 (18.2)	5 (2.7)	
Asia	469 (48.7)	31 (17.0)	
Europe	2 (0.2)	0 (0.0)	
Oceania	4 (0.4)	1 (0.5)	
Pre-Travel Advice (n ^b)	774	148	< 0.001
Yes	278 (35.9)	29 (19.6)	
Prophylaxis (n ^b)	214	82	0.267
Yes	54 (25.2)	15 (18.3)	
Symptoms (n ^b)	964	181	
Fever			0.049
Yes	829 (86.0)	166 (91.7)	
Night Sweats			0.850
Yes	336 (34.9)	65 (35.9)	
Headache			0.001
Yes	492 (51.0)	117 (64.6)	
Sore Throat			< 0.001
Yes	243 (25.2)	22 (12.2)	
Cough			0.019
Yes	323 (33.5)	44 (24.3)	
Arthralgia/ Myalgia			0.084
Yes	342 (35.5)	77 (42.5)	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Diarrhea			0.032
Yes	257 (26.7)	34 (18.8)	
Splenomegaly			0.277
Yes	21 (2.2)	7 (3.9)	
Duration ^c (mean days [sd])	48.98 (77.74)	239.00 (665.62)	< 0.001
<i>Plasmodium</i> Species Type (n) (%)			
<i>P. falciparum</i>	-	144 (65.8)	
<i>P. vivax</i>	-	54 (24.7)	
<i>P. ovale</i>	-	17 (7.76)	
<i>P. malariae</i>	-	4 (1.83)	

^a The tests used for categorical variables are chi-square with continuity correction and ANOVA for continuous variables with equal variance assumption

^b Missing values are excluded from the table

^c The duration of stay in the malaria-endemic areas for travelers in days

398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427

Confidential

1
2
3 428
4 429
5 430
6 431
7 432
8 432

9
10 Table 2: The odds ratios and corresponding 95% CIs and p-values for the multivariate
11 regression analysis of cases and controls for various exposure measures (N = 931)

12	Variable	OR (95% CIs)	Pr (> z)
13	Gender		
14	Female	1.00	
15	Male	2.70 (1.56 - 4.80)	< 0.001
16			
17	Age		
18	Children	1.00	
19	Adults	3.62 (1.66 - 8.84)	< 0.001
20			
21	Reason		
22	Tourists	1.00	
23	Business	1.12 (0.35 - 3.26)	0.84
24	VFR	2.82 (1.42 - 5.92)	< 0.001
25			
26	Continent		
27	Other	1.00	
28	Africa	11.52 (6.33 - 22.05)	< 0.001
29			
30	Pre-Travel Advise		
31	No	1.00	
32	Yes	0.38 (0.20 - 0.70)	< 0.001
33			
34	Duration (> 2 weeks)		
35	No	1.00	
36	Yes	1.40 (0.60 - 3.67)	0.46
37	Bolded p-values are those variables with a significant p-value, using an $\alpha = 0.05$, in 38 comparison to its reference		

39 433
40 434
41 435
42 436
43 436
44
45
46 437
47
48
49 438
50
51
52 439
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47




Figure 1




Figure 2

338x190mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3

Supplementary Material

Random selection of controls

Using software R version 1.1.453, random numbers were generated between 1 and the maximum number of malaria tests conducted for the year, such that five controls could be selected for each case within that specific year. This number corresponded to the laboratory accession number from the Calgary Laboratory Services (CLS) database which was used to identify the participant. A ratio of greater than 4 controls to 1 case was felt unlikely to increase the study power further, yet a 5:1 ratio was selected to allow for missing data.

The rationale for cases and controls

Given the objective of the study, malaria positive individuals presented themselves as the outcome of interest. Hospital controls were selected from the CLS database from among those who have undergone a malaria test to ensure that both the cases and controls got tested for malaria by the same diagnostic methods and that controls only included those who did not have malaria within the specificity of the diagnostic tests used. This was to limit the information bias due to incorrect outcome ascertainment. No measures were taken to mitigate selection bias that arose due to hospital control selection in this study. Controls and cases were matched by year to eliminate any variation due to immigration/emigration rates and other factors that impact travel by year.

Epidemiological risk factors

Variables that were analyzed for this study included age, gender, the reason for visit, continent visited, if pre-travel advice was sought, if malarial prophylaxis was taken and duration of stay. Symptoms of cases and controls were also recorded. Our primary exposure of interest, VFR was defined as those who travelled primarily for the purpose of visiting friends and relatives and those who had a difference in risk for malaria exposure due to a history of recent travel to a malaria endemic region, disregarding the differences in ethnicity and immigration status of this population (1). VFR was a category under Reason for Visit variable in the Malaria History Form (MHF) and other categories included *Tourists*, *Business*, *New Immigrant* and *Visitor*. The two main other purposes of visit categories were *Tourist* travelers and *Business* travelers which included those who self-declared themselves as visiting a malaria endemic region for pleasure (without visiting family or friends) or for work-related purposes respectively. Information regarding age and gender was obtained from the CLS database. Age was a categorical variable of *Child* or *Adult*, where participants who are under 16 years of age were defined as a child. Gender was a categorical variable of *Female* and *Male*. Continent visited was derived from the country indicated in the *Travel Destination* section in MHF and categorized as either visiting *Africa* or *Other* continent for the statistical analyses. Africa was used as a primary comparator to other continents due to past evidence suggesting imported malaria mainly resulted from travel to the

1
2
3 African continent (2-4). Pre-travel advice sought was also a categorical variable of *Yes* or *No*
4 which was collected from the MHF questionnaire that was completed before malaria testing.
5 Malaria prophylaxis taken was a *Yes* or *No* categorical variable and information for this was also
6 collected from the MHF. Participants were categorized under *Yes* if they indicated that they have
7 taken any one or more of the malaria prophylaxes listed under *Malaria Prophylaxis Taken* in the
8 MHF and *No* if they indicated *None*. Duration of stay was derived from information provided in
9 the MHF under *Departure Date* and *Date of Arrival in Canada*. This was calculated in days and
10 later categories as less than or equal to two weeks of stay (≤ 2 weeks) or longer than 2 weeks of
11 stay (>2 weeks). First three digits of the zip code obtained from the CLS database, complemented
12 by MHFs was used to determine the Ward of residence in Calgary and to develop an incidence
13 map of Malaria cases in Calgary according to 2016 census population data.
14
15
16

17 *Statistical analysis*

18
19 For descriptive analysis, chi-square tests with continuity correction were used for categorical
20 variables whereas ANOVA with the assumption of equal variance was used for continuous
21 variables. This included all the cases and controls (N = 1348) selected for this study. Incidences
22 of malaria map were drawn according to population demographics from the census in 2016 and
23 using geographical boundaries of Wards from Open Calgary (5). For the multivariable logistic
24 regression, numerous variables were examined including the effects of age, VFR status, region
25 traveled to, pre-travel advice, duration and gender on testing positive for malaria. Evidence for
26 effect measure modification between gender and VFR and continent travel to and VFR on a
27 multiplicative scale was analyzed by including interaction variables in multivariate regressions. A
28 chi-square test was used to analyze the differences in taking prophylaxis, taking pre-travel advice
29 and duration of stay between VFR travelers and other travelers. Missing data were not examined
30 further using imputations methods or sensitivity analysis.
31
32
33

34 *Data access and cleaning methods*

35
36 Investigators only had access data extracted from the CLS database regarding all malaria tests
37 conducted in the CLS during the study period. They were stored and cleaned using Microsoft
38 Excel (Version 1808) to remove repeated tests for individuals occurring within three months.
39 Individuals from the CLS database was linked to individuals from the MHF using MIL numbers.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary Table 1: Odds ratios, 95% CIs and p-values for the multivariate regression examining the evidence for EMM between VFR status and Gender (N = 931)

Variable	OR	95 % (CIs)		Pr(> z)
		2.50%	97.50%	
Gender				
Female	1.00			-
Male	2.77	1.19	7.23	0.02
EMM Male & VFR				
No	1.00			-
Yes	0.59	0.21	1.58	0.31
Reason				
Tourist	1.00			-
VFR	4.22	1.93	10.62	<0.001

Supplementary Table 2: Odds ratios, 95% CIs and p-values for the multivariate regression examining the evidence for EMM between VFR status and region visited (N = 931)

Variable	OR	95 % (CIs)		Pr(> z)
		2.50%	97.50%	
Continent				
Other	1.00			-
Africa	8.36	3.46	23.39	<0.001
Africa & VFR				
No	1.00			-
Yes	1.30	0.41	3.80	0.64
Reason				
Tourist	1.00			-
VFR	2.39	0.97	6.73	0.07

Supplementary Figure 1: A copy of the malaria history form where information regarding the cases and controls were collected from. Missing information was supplemented with data from the CLS database when available.

For Lab Use Only

Ebola/VHF Risk ([National Case Definition: Ebola Virus Disease \(EVD\) - Public Health Agency of Canada](#))
 If patient is at risk for Viral Hemorrhagic Fever call the Medical Officer of Health (403-264-5616) immediately before testing. Alternately contact the MOC (403-770-3757) if the MOH is unavailable.

<input type="checkbox"/> ACUTE MALARIA: Symptomatic patient only Complete both Travel & Clinical History sections	Patient Full Name: (first and last) <input style="width: 100%;" type="text"/>
<input type="checkbox"/> MALARIA SCREEN: Asymptomatic patient Complete Travel history section below Note: results provided within 24h of specimen collection	PHN# or Unique # identifier: <input style="width: 100%;" type="text"/>
<input type="checkbox"/> PRE-EMPLOYMENT REQUEST	Ordering Physician: <input style="width: 100%;" type="text"/>
	Required - after hours contact #: <input style="width: 100%;" type="text"/>

TRAVEL HISTORY	CLINICAL HISTORY										
Pre-travel advice from Clinic/physician: <input type="checkbox"/> Yes <input type="checkbox"/> No	Onset of Symptoms <input style="width: 20px;" type="text"/> / <input style="width: 20px;" type="text"/> / <input style="width: 20px;" type="text"/> YYY Y MMM DD										
Reason for travel: Tourism <input type="checkbox"/> Visiting friends / relatives <input type="checkbox"/> Business <input type="checkbox"/> Visitor to Canada <input type="checkbox"/> New Immigrant <input type="checkbox"/>	Symptoms and Signs: (Check all that are present)										
	Fever / Chills / Rigors <input type="checkbox"/> Night Sweats <input type="checkbox"/> Headache <input type="checkbox"/> Sore Throat <input type="checkbox"/> Cough <input type="checkbox"/> Arthralgia / Myalgia <input type="checkbox"/> Diarrhea <input type="checkbox"/> Splenomegaly <input type="checkbox"/>										
Countries with malaria visited: For affected countries refer to: Malaria Risk - Public Health Agency of Canada	Malaria Prophylaxis taken? Indicate below:										
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 50%;">Country:</th> <th style="width: 50%;">Departure Date:</th> </tr> </thead> <tbody> <tr><td><input style="width: 100%;" type="text"/></td><td><input style="width: 100%;" type="text"/></td></tr> <tr><td><input style="width: 100%;" type="text"/></td><td><input style="width: 100%;" type="text"/></td></tr> <tr><td><input style="width: 100%;" type="text"/></td><td><input style="width: 100%;" type="text"/></td></tr> <tr><td><input style="width: 100%;" type="text"/></td><td><input style="width: 100%;" type="text"/></td></tr> </tbody> </table>	Country:	Departure Date:	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>	None <input type="checkbox"/> Chloroquine <input type="checkbox"/> Mefloquine <input type="checkbox"/> Doxycycline <input type="checkbox"/> Malarone <input type="checkbox"/> Other (list): <input type="checkbox"/>
Country:	Departure Date:										
<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>										
<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>										
<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>										
<input style="width: 100%;" type="text"/>	<input style="width: 100%;" type="text"/>										
Date of arrival in Canada <input style="width: 20px;" type="text"/> / <input style="width: 20px;" type="text"/> / <input style="width: 20px;" type="text"/> YYY Y MMM DD	On Malaria Treatment: <input type="checkbox"/> No <input type="checkbox"/> Yes										

Questions? Call the Laboratory Information Centre at 403-770-3600

References

1. Barnett ED, MacPherson DW, Stauffer WM, Loutan L, Hatz CF, Matteelli A, et al. The visiting friends or relatives traveler in the 21st century: time for a new definition. *J Travel Med.* 2010;17(3):163-70.
2. Matteelli A, Carvalho AC, Bigoni S. Visiting relatives and friends (VFR), pregnant, and other vulnerable travelers. *Infect Dis Clin North Am.* 2012;26(3):625-35.
3. Legros F, Bouchaud O, Ancelle T, Arnaud A, Cojean S, Le Bras J, et al. Risk factors for imported fatal *Plasmodium falciparum* malaria, France, 1996-2003. *Emerg Infect Dis.* 2007;13(6):883.
4. Hendel-Paterson B, Swanson SJ. Pediatric travelers visiting friends and relatives (VFR) abroad: illnesses, barriers and pre-travel recommendations. *Travel Med Infect Dis.* 2011;9(4):192-203.
5. Ward Boundaries [Internet]. 2018 [cited August 2018]. Available from: <https://data.calgary.ca/Government/Ward-Boundaries/r9vx-mhnf>.

Confidential